安全性薬理学の予測性を高めるための微小電極アレイ上の心筋細胞のレーザー誘起活動電位様測定

Executive Industry Relevance

Laser-induced action potential-like (liAP) measurements on microelectrode arrays (MEA) enable more predictive and sensitive detection of drug-induced cardiotoxicity in early safety pharmacology. By transforming extracellular field potentials into intracellular-like action potentials, this method enhances mechanistic de-risking and supports higher predictive confidence for arrhythmia risk. The approach strengthens portfolio triage by providing actionable data at critical discovery and preclinical inflection points.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Enables direct interrogation of ion channel function and arrhythmogenic mechanisms in cardiomyocytes.
• Improves biological de-risking by revealing subtle proarrhythmic membrane potential fluctuations.
• Supports functional target validation for cardiac safety liabilities in candidate molecules.
• Facilitates predictive confidence in early-stage compound triage.

Screening & Assay Development

• Prepares validated cardiomyocyte systems for high-content safety screening workflows.
• Delivers standardized, reproducible, and quantitative action potential measurements.
• Enables scalable, platform-based evaluation of compound-induced electrophysiological changes.
• Supports reliable detection of early afterdepolarizations (EADs) and ectopic beats as proarrhythmic markers.

Translational & Preclinical Research

• Aligns in vitro electrophysiological readouts with disease-relevant arrhythmia biomarkers.
• Provides continuity from discovery through preclinical cardiac safety assessment.
• Enables risk-adjusted advancement decisions based on mechanistic arrhythmia data.
• Enhances predictive de-risking for late-stage candidate selection.

Pipeline & Workflow Integration

This method integrates into the discovery-to-preclinical continuum, bridging early safety assessment and translational cardiac risk evaluation.

• Discovery Biology: Supports hypothesis testing for ion channel involvement in drug-induced arrhythmia.
• Screening: Delivers reproducible, quantitative action potential data for compound comparison.
• Analytics: Provides high-resolution measurements of AP duration, EADs, and ectopic activity for statistical analysis.
• Translational Research: Connects in vitro findings to clinical arrhythmia risk markers.
• Enterprise Reuse: Establishes a reusable MEA-based platform for ongoing cardiac safety profiling.

Operational & Enterprise Impact

• Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in cardiac safety assessment.
• Operational Value: Standardizes and scales electrophysiological measurements across compound libraries.
• Strategic Value: Enables informed go/no-go decisions and capital-efficient portfolio management.
• Portfolio Impact: Supports risk-adjusted prioritization and advancement of safer drug candidates.

Implementation Considerations

• Requires expertise in electrophysiology and MEA operation.
• Needs access to laser poration instrumentation and compatible MEA systems.
• Demands cross-team standardization of assay protocols and data analysis.
• May require adaptation for different cardiomyocyte sources or disease models.
• Focus and timing of laser poration are critical for reliable data acquisition.

Biopharma FAQs